Clinical Daily Summary
Clinical Daily Summary: What Happened on October 5, 2026
Vaxcyte’s 31-valent vaccine meets Phase 3 endpoints in first trial
Phase 3 results put survodutide, tozorakimab and Genmab’s Rina-S in focus, with tolerability and follow-up data shaping the picture.
Today in brief
Vaxcyte said VAX-31 met the primary endpoints in its first Phase 3 trial, which compared antibody responses with Pfizer’s and Merck’s vaccines in more than 3,500 adults.12 Boehringer Ingelheim’s survodutide met both primary endpoints in a Phase 3 obesity trial, but gastrointestinal events led 18% of treated participants to stop therapy.3 AstraZeneca said tozorakimab reduced COPD exacerbations in two Phase 3 trials. Genmab reported a 45.9% response rate for Rina-S in platinum-resistant ovarian cancer.45
Vaxcyte’s vaccine meets primary endpoints in its first Phase 3 trial
Vaxcyte said VAX-31 met the primary endpoints in the first of three planned Phase 3 trials, which enrolled more than 3,500 adults aged 50 and older.12 The study measured antibody responses after participants received VAX-31 or one of two approved vaccines, Pfizer’s Prevnar and Merck’s Capvaxive.1
VAX-31 is designed to cover 31 pneumococcal serotypes, compared with 20 for Prevnar and 21 for Capvaxive.1 The result is from one of three Phase 3 trials and does not establish how the vaccine will perform across the full program.2
Tozorakimab reduced COPD exacerbations in two Phase 3 trials
AstraZeneca said its antibody tozorakimab cut COPD exacerbations by up to 30% among current and former smokers in the OBERON and TITANIA trials.4 The trials compared monthly add-on treatment with placebo for 52 weeks in people whose COPD had worsened despite standard inhaled therapy.4
Among former smokers in the primary efficacy group, annual moderate or severe exacerbation rates were 1.34 to 1.37 with tozorakimab, versus 1.90 to 2.07 with placebo.4 The drug’s apparent effect was largest in participants with blood eosinophil counts above 300 cells per microliter, though the trials also found benefit at lower counts.4
Side effects were broadly similar between groups, apart from more injection-site reactions with tozorakimab.4 Investigators did not consider observed deaths and cardiovascular events drug-related. They recorded 13 events in the tozorakimab group, combining major cardiovascular events with serious adverse events that resulted in death, compared with five in the placebo group.4 AstraZeneca has submitted the drug to the FDA and expects an agency decision in the first quarter of 2027.4
Survodutide meets both Phase 3 endpoints, but treatment stops were more common
Boehringer Ingelheim’s survodutide met both primary endpoints in SYNCHRONIZE-2, a 76-week trial in adults with overweight or obesity and type 2 diabetes.3 Among 755 participants, mean weight loss reached 13.1% with survodutide and 3.1% with placebo in an analysis that assumed participants stayed on treatment.3
When the analysis included outcomes regardless of whether participants stopped treatment, weight loss was 9.8% with the 6.0-mg dose and 8.2% with the 3.6-mg dose, versus 3.9% with placebo.3 Gastrointestinal events led 18% of survodutide recipients to discontinue treatment, compared with 1.2% of placebo recipients. Discontinuations usually occurred during dose escalation.3
The trial had no active-drug comparator, so survodutide’s performance against approved incretin therapies remains unknown.3 Boehringer said newer studies allow more flexible dose increases, which the company believes may reduce gastrointestinal discontinuations.3
Rina-S produced a 45.9% response rate in ovarian cancer study
Genmab’s Rina-S produced a confirmed objective response in 45.9% of 109 patients with platinum-resistant ovarian cancer in the Phase I/II RAINFOL-01 trial.56 Five patients had complete responses. Median response duration was 12.1 months, and median progression-free survival was 9.5 months.5
More than half of participants had received three or four prior treatment regimens, and all had previously received bevacizumab and a taxane.5 Serious adverse events affected about one-third of participants, and 5.5% stopped treatment because of adverse events. Common blood-related events included neutropenia and anemia.56
Genmab is testing Rina-S in four Phase 3 trials in ovarian and endometrial cancers.6
Also worth knowing
-
B
Biogen’s Phase 2 AMETHYST data showed skin clearance and CLASI-70 responses with litifilimab continued to improve through week 52. The extended results lack a placebo comparison and have not been peer reviewed. Phase 3 results are expected in the first half of 2027.7
-
N
A Phase 3 trial in China found all three tested doses of oral safiglipron non-inferior to dapagliflozin for HbA1c change at week 32. In a separate analysis, the 90-mg dose also met the trial’s superiority criterion.8
-
Mayo Clinic researchers found that rapid whole-genome sequencing diagnosed a genetic condition in 46.9% of 175 children with unexplained neurological symptoms. Results changed care for 54 of the 82 diagnosed children.9
-
In a first-in-human Phase 1 study of 10 women with advanced osteoporosis, sugar-modified stem cells were not linked to treatment-related serious adverse events. Researchers said the small trial and concurrent bone treatments leave efficacy uncertain.10
-
At the European Academy of Dermatology and Venereology meeting, Nektar reported full skin clearance at week 52 in 22% of participants on monthly rezpegaldesleukin and 18% on quarterly dosing for atopic dermatitis.11
Also published
- The BioPharm Brief: Obesity Data and Manufacturing Shape Drug Progress BioPharm International
- Vaxcyte's pneumococcal jab exceeds expectations pharmaphorum
- GLP-1RA non-responders: tackling a hidden challenge behind the obesity epidemic Pharmaceutical Technology
- The Most Surprising Development in GLP-1s Pharmaceutical Executive
- The hidden pandemic within the pandemic: How COVID-19 impacted sepsis – and what comes next pharmaphorum
- STAT+: Divergent trial results on cancer vaccines have the field grappling with hard questions STAT Biotech
- AstraZeneca’s tozorakimab cuts COPD exacerbations by up to 34% in phase 3 trials Pharmafile